Indian vaccine manufacturer Bharat Biotech on Wednesday announced results of Phase 3 clinical trials of its Covid-19 vaccine candidate, Covaxin, saying the vaccine demonstrates interim clinical efficacy of 81 per cent.
Bharat Biotech said the Phase 3 clinical trials for Covaxin involved 25,800 volunteers, making it the "largest trials ever conducted in India" in collaboration with the Indian Council of Medical Research (ICMR)."Covaxin has demonstrated 81 per cent interim efficacy in preventing Covid-19 in those without prior infection after the second dose," Bharat Biotech said.
These results were based on the first interim analysis of Covaxin.
"With today's results from our Phase 3 clinical trials, we have now reported data on our Covid-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants," Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech said.
Dr Ella added that apart from demonstrating high clinical efficacy against Covid-19, Covaxin also provides "significant immunogenicity against the rapidly emerging variants" of the virus causing Covid-19.
Covaxin is India's indigenously developed and manufactured Covid-19 vaccine candidate and has been granted emergency use approval by the government.
Covishield, the vaccine developed by Oxford University and AstraZeneca and manufactured by the Serum Institute of India is the second vaccine that has been granted emergency use approval in the country.
Both the vaccines are being used in the nationwide Coivd-19 vaccination drive that started on January 16.On Tuesday, Prime Minister Narendra Modi also took his first shot of Covaxin at AIIMS, New Delhi.
Source: India Today